86 5.3.2 Review question: In people with suspected heart failure who also have chronic kidney disease, what is the clinical and cost effectiveness of N- terminus pro-B-type natriuretic peptide (NT-proBNP) compared to B-type natriuretic peptide (BNP), when each is followed by the appropriate patient pathway, in order to improve patient outcomes? 87 5.3.6 Recommendations and link to evidence 90 5.4 Recommendations for diagnosing heart failure 103 5.4.1 Symptoms, signs and investigations 103 5.4.2 Heart failure caused by valve disease 104 5.4.3 Reviewing existing diagnoses 104 5.5 Cardiac Magnetic Resonance Imaging (cMRI) 105 5.5.2 Review question: In people with heart failure what is the clinical and cost effectiveness of cardiac MRI followed by the appropriate patient pathway? 105 5.5.6 Recommendations and link to evidence 106 6 Treating Heart Failure 109 6.1.1 Salt and fluid restriction 109 6.1.2 Recommendations on lifestyle 120 6.2 Pharmacological treatment 121 6.2.2 Beta-blockers in people with heart failure and atrial fibrillation 122 6.2.3 Mineralocorticoid Receptor Antagonists in HFPEF 134 6.2.4 Mineralocorticoid Receptor Antagonists in HFREF 144 6.2.5 Iron supplementation for iron deficiency in heart failure 159 6.2.6 Pharmacological treatment for heart failure in people with heart failure and chronic kidney disease 180 6.2.7 All recommendations for the pharmacological treatment of heart failure 202 6.3 Invasive procedures 207 6.3.1 Coronary revascularisation 207 6.3.2 Recommendations for invasive procedures 222 Chronic Heart Failure Contents NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 7 Rehabilitation in chronic heart failure 223 7.1 Home-based versus centre-based rehabilitation 223 7.1.2 Review question: What is the clinical and cost effectiveness of home-based versus centre-based rehabilitation (that includes an exercise element) for people with heart failure (HF)? 